His main research concerns Guillain-Barre syndrome, Immunology, Antibody, Molecular mimicry and Campylobacter jejuni. His Guillain-Barre syndrome research incorporates themes from Internal medicine, Pathogenesis, Campylobacter Jejuni Infection and Weakness. His research in Immunology focuses on subjects like Hepatitis E virus, which are connected to Hepatitis and Hepatitis E.
He has researched Antibody in several fields, including Mechanism of action, Ex vivo and Motor nerve. His Molecular mimicry study incorporates themes from Epitope, Autoimmune disease and Virology. His research in Campylobacter jejuni intersects with topics in Ganglioside, Campylobacter, Response to treatment and Microbiology.
Bart C. Jacobs mainly investigates Guillain-Barre syndrome, Immunology, Antibody, Campylobacter jejuni and Virology. His Guillain-Barre syndrome research is multidisciplinary, incorporating elements of Internal medicine, Disease, Serology and Weakness. His Immunology research includes elements of Mycoplasma pneumoniae and Polyneuropathy.
His study in Antibody is interdisciplinary in nature, drawing from both Immune system and Ganglioside. Bart C. Jacobs has researched Campylobacter jejuni in several fields, including Genotype, Campylobacter and Enteritis, Microbiology. Bart C. Jacobs works mostly in the field of Virology, limiting it down to concerns involving Hepatitis E virus and, occasionally, Hepatitis E and Hepatitis.
Bart C. Jacobs mainly focuses on Guillain-Barre syndrome, Polyradiculoneuropathy, Internal medicine, Antibody and Pediatrics. The concepts of his Guillain-Barre syndrome study are interwoven with issues in Serology, Campylobacter jejuni, Pandemic and Virology. His work carried out in the field of Campylobacter jejuni brings together such families of science as Serum antibody and Microbiology.
Bart C. Jacobs has included themes like Dermatology, Incidence, Polyneuropathy and Intensive care medicine in his Polyradiculoneuropathy study. Bart C. Jacobs usually deals with Internal medicine and limits it to topics linked to Gastroenterology and Alemtuzumab. His Antibody research is under the purview of Immunology.
Guillain-Barre syndrome, Pediatrics, Polyradiculoneuropathy, Observational study and Virology are his primary areas of study. His Guillain-Barre syndrome research incorporates themes from Internal medicine, Cohort and Serology. His studies in Serology integrate themes in fields like Mycoplasma pneumoniae, Virus, Dengue virus and Hepatitis E virus.
His work in Pediatrics addresses subjects such as Disease course, which are connected to disciplines such as Clinical endpoint and Plasmapheresis. His Polyradiculoneuropathy research includes themes of Prevalence, Incidence, Checklist and Meta-analysis, Random effects model. His Virology research is multidisciplinary, relying on both Haemophilus influenzae and Severe acute respiratory syndrome coronavirus 2, Pandemic, Coronavirus disease 2019.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Hugh J Willison;Bart C Jacobs;Pieter A van Doorn.
The Lancet (2016)
The spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study
B. C. Jacobs;P. H. Rothbarth;F.G.A. van der Meché;P. Herbrink.
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
Pieter A van Doorn;Liselotte Ruts;Bart C Jacobs.
Lancet Neurology (2008)
Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
Bianca van den Berg;Christa Walgaard;Judith Drenthen;Christiaan Fokke.
Nature Reviews Neurology (2014)
Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria
Christiaan Fokke;Bianca van den Berg;Judith Drenthen;Christa Walgaard.
The Guillain–Barré syndrome: a true case of molecular mimicry
C. Wim Ang;Bart C. Jacobs;Jon D. Laman.
Trends in Immunology (2004)
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.
Bart C. Jacobs;Pieter A. van Doorn;Anne P. Tio-Gillen;Leo H. Visser.
Annals of Neurology (1996)
A clinical prognostic scoring system for Guillain-Barré syndrome
Rinske van Koningsveld;Ewout W. Steyerberg;Richard Ac C. Hughes;Anthony V. Swan.
Lancet Neurology (2007)
Early recognition of poor prognosis in Guillain-Barré syndrome
C. Walgaard;H.F. Lingsma;L. Ruts;P.A. van Doorn.
The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome
Peggy C.R. Godschalk;Astrid P. Heikema;Michel Gilbert;Tomoko Komagamine.
Journal of Clinical Investigation (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: